Company news

Soligenix, Inc. news in 2023

Soligenix, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease

November 29, 2023

Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results

November 12, 2023

Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures

September 24, 2023

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders

September 21, 2023

Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results

August 20, 2023

HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

August 9, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

July 10, 2023

Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

May 15, 2023

Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results

May 14, 2023

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

May 10, 2023

Soligenix Announces Closing of $8.5 Million Public Offering

May 8, 2023

Soligenix Announces Pricing of $8.5 Million Public Offering

May 4, 2023

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

May 3, 2023

Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

May 2, 2023

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

April 30, 2023

Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

April 23, 2023

Soligenix Provides Regulatory Update on HyBryte™

April 13, 2023

Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302

April 4, 2023

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

April 2, 2023

Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results

March 30, 2023

Decks in 2023